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Résumé 
Le ROTEM est un test de coagulation réalisable au près du malade qui permet d'objectiver la 
coagulopathie, de distinguer la contribution' des différents éléments du système de coagulation et 
de cibler les produits procoagulants comme le plasma frais congelé (PFC), les plaquettes, le 
fibrinogène et les facteurs de coagulation purifiés ou les antifibrinolytiques. 
3 des tests disponibles pour le ROTEM sont: EXTEM, INTEM, HEPTEM. Le premier test est 
stable sous hautes doses d'héparine alors que le deuxième est très sensible à sa présence. Dans le 
dernier test on rajoute de l'héparinase pour mettre en évidence l'éventuel effet résiduel de 
l'héparine en le comparant à l'INTEM. 
Idéalement, le ROTEM devrait être effectué avant la fin du bypass cardiopulmonaire (CEC), 
donc sous anticoagulation maximale pas héparine, afin de pouvoir administrer des produits pro-
coagulants dans les délais les plus brefs et ainsi limiter au maximum les pe1ies sanguines. En 
effet la commande et la préparation de certains produits procoagulants peut prendre plus d'une 
heure. 
Le but de cette étude est de valider l'utilisation du ROTEM en présence de hautes concentrations 
d'héparine. Il s'agit d'une étude observationnelle prospective sur 20 patients opérés électivement 
de pontages aorto-coronariens sous CEC. 
Méthode: l'analyse ROTEM a été réalisée avant l'administration d'héparine (TO), 10 minutes 
après l'administration d'héparine (Tl), à la fin de la CEC (T2) et 10 minutes après la 
neutralisation de l'anticoagulation avec la protamine (T3). L'état d'héparinisation a été évalué 
par l'activité anti-Xa à Tl,T2,T3. 
Résultats : Comparé à TO, la phase de polymérisation de la cascade de coagulation et 
l'interaction fibrine-plaquettes sont significativement détériorées par rapp01i à Tl pour les 
canaux EXTEM et HEPTEM. A T2 l'analyse EXTEM et INTEM sont comparables à celles de 
EXTEM et HEPTEM à T3. 
Conclusion: les hautes doses d'héparine utilisées induisent une coagulopathie qui reste stable 
durant toute la durée de la CEC et qui persiste même après la neutralisation de l'anticoagulation. 
Les mesures EXTEM et HEPTEM sont donc valides en présence de hautes concentrations 
d'héparine et peuvent être réalisés pendant la CEC avant l'administration de protamine. 
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CONTEXT Rotational thromboelastometry (ROTEM) is a 
whole blood point-of-test used to assess the patient's coagu· 
lation status. Three of the available ROTEM tests are EXTEM, 
INTEM and HEPTEM. ln the latter, heparinase added to the 
INTEM reagent inactivates heparin to reveal residual heparin 
effect. Performing ROTEM analysis during cardiopulmonary 
bypass (CPB) might allow the an~esthesiologist to anticipate 
the need for blood products. 
OBJECTIVE The goal of this study was to validate ROTEM 
analysis in the presence of very high heparin concentrations 
during CPB. 
DESIGN Prospective, observational trial. 
SETTING Single University Hospital. 
PARTICIPANTS Twenty patients undergoing coronary artery 
bypass grafting. 
MAIN OUTCOME MEASURE ROTEM analysis was per· 
formed before heparin administration (TO), 10 min after 
heparin (T1 ), at the end of CPB (T2) and 10 min after 
protamine (T3). The following tests were performed: EXTEM, 
1 ntrod uction 
Cardiac surgery using cardiopulmonary bypass (CPB) is 
frequently complicated by haemorrhage requiring trans-
fusion of blood products. 1 The Society of Thoracic Sur-
geons (STS) Adult Cardiac Surgery database shows that 
up to 50% of patients undergoing cardiac surgery receive 
blood transfusions2 and this rate is increased in complex 
procedures. 3 Transfusion of blood products has been 
shown to negatively influence short-term and long-term 
outcomes.4•5 
Classically, the activated clotting time (ACT) is used 
during CPB to monitor heparin anticoagulation. The 
INTEM, and HEPTEM. Heparin concentrations were 
measured at T1 and at the end of bypass (T2). 
RESUL TS At T1, EXTEM differed from baseline for coagu· 
lation time: +26. 7 s (18.4 to 34.9, P < 0.0001 ), œ: -3° (1.0 
to 5.4, P= 0.006) and A 10: -4.4 mm (2.3 to 6.5, 
P= 0.0004). INTEM at TO was different from HEPTEM at 
T1 for coagulation time: + 47 s (34.3 to 59.6, P>0.0001), 
A 10: -2.3 mm (0.5 to 4.0, P= 0.01) and œ -2° (1.0 to 3.0; 
P= 0.0007). At T2, ail parameters in EXTEM and HEPTEM 
related to fibrin·platelet interaction deteriorated significantly 
compared to T1. At T3, EXTEM and INTEM were comparable 
to EXTEM and HEPTEM at T2. 
CONCLUSION HEPTEM and EXTEM measurements are 
valid in the presence of very high heparin concentrations 
and can be performed before protamine administration in 
patients undergoing cardiac surgery with CPB. 
TRIAL REGISTRATION clinicaltrials.gov identifier 
NCT01455454. 
Published online xx month 2013 
ACT test is strongly dependent on, and correlates almost 
linearly with, high heparin levels. At the end of bypass, 
the usefulness of the ACT is limited due to this strong 
heparin dependency, as any underlying coagulopathy will 
be masked and can only be revealed by more sophisti-
cated viscoelastic coagulation tests. The use of viscoe-
lastic, whole blood point-of-care (POC) coagulation tests, 
in combination with transfusion protocols, reduces peri-
operative blood Joss and transfusion requirements in 
high-risk procedures. 6 In cardiac surgery, the se tests 
are usually performed after heparin reversai with 
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protamine, but several authors have advocated the use of 
these tests during CPB, before heparin reversa!, arguing 
that earlier detection of coagulopathies saves precious 
time and may result in the more effective use of haemo-
static blood products. No data on blood loss were pre-
sented by these authors. 7' 8 A recent study, however, 
showed a reduction in blood loss and improved survival 
when bleeding was treated using an algorithm based on 
rotal:ional thromboelastometry (ROTEJvl; TEM Inter-
national, M ünich, Germany). Weber et al. 9 found a shorter 
'bleed-to-treat' time to be one of the contributing factors 
leading to the improved outcome. 
POC-based treatment algorithms often define precise 
thresholds for the initiation of procoagulant therapy, 10 
and measurement errors may lead to unwarranted trans-
fusion of fresh frozen plasma (FFP), platelets or procoa-
gulant drugs. Validation of these tests in the presence of 
high heparin levels is, therefore, necessary for them to be 
used during CPB. 
Tuman et al. 11 validated the use of a heparinase-modified 
thromboelastography (TEG) during CPB. In this study, 
TEG was activated by kaolin and was, therefore, highly 
sensitive to the effects of heparin. Heparinase is an 
enzyme isolated frorh Flavobacterium heparit111111 that 
cleaves the heparin polymer into inactive dimers and 
oligomers, allowing for the assessment of the underlying 
coagulation status of the patient. 
In ROTEIV1, coagulation can be initiated using either the 
contact activator ellagic acid in the INTEM test or 
recombinant tissue factor (rTF) in the EXTEM test. 
As with kaolin, the former is highly sensitive to heparin 
and a heparinase-modified INTEM, called HEPTEM, is 
available. Conversely, according to the manufacturer, 
rTF remains stable in the presence of heparin concen-
trations up to 5 IU ml-1. The reliability of ROTEM in 
the presence of very high concentrations of heparin has, 
to our knowledge, not been tested. 
The primary aim of this study was to compare ROTEM 
results before and after protamine administration, in 
patients undergoing cardiac surgery with CPB. A signifi-
cant difference would justify heparin reversai before 
coagulation testing. Conversely, if the results are com-
parable, therapeutic decisions based on a ROTEM-based 
algorithm will be the same whether the test has been 
performed before or after protamine administration, 
potentially saving time. The secondary aims were to 
evaluate the influence of heparin administration and 
CPB on the ROTEM profile. 
Methods 
This prospective study was performed in the University 
Hospital of Lausanne, Switzerland from September 2010 
to September 2011. Ethical approval for this study 
(Ethical Committee nr. 123/10) was provided by the 
Ethical Committee of the Canton Vaud (Commission 
Eur J Anaesthesiol 2013; 30:1 -8 
Cantonal d'Ethique de la Recherche sur l'Etre Humain, 
Lausanne, Switzerland) on 2 June 2010 (Chairperson 
Prof. M. Burnier). Written informed consent was 
obtained from all participants. Consecutive patients 
presenting for elective coronary artery bypass grafting 
were screened for enrolment. Inclusion criteria were 
patients aged between 18 and 65 years undergoing 
elective coronary artery bypass grafting, which was 
anticipated to be uncomplicated. Exclusion criteria were 
known congenital or acquired coagulopathies, hepatic 
disease, kidney disease requiring dialysis and preopera-
tive treatment with oral anticoagulants, heparin, low 
molecular weight heparin or antiplatelet drugs other than 
aspirin. The latter was not an exclusion criterion owing to 
the high prevalence of aspirin therapy in this patient 
group. 
Ail patients were premedicated with 7.5 mg of oral mid-
azolam. Induction of anaesthesia was accomplished with 
intravenous midazolam 0.05 to 0.1 mgkg-1, propofol 
0.5 to lmgkg-1 and fentanyl 4µ,gkg- 1. Muscle relaxa-
tion was obtained using cisatracurium 0.2mgkg-1. 
Anaesthesia was maintained using sevoflurane before 
and after CPB, and a propofol infusion during normother-
mic CPB, titrated to a bispectral index (BIS) value 
between 40 and 60. 
After an initial bolus of 300 IU kg-', heparin sodium 
derived from porcine intestinal mucosa (Braun Medical 
AG, Sempach, Switzerland) was titrated to achieve ACT 
values more than 480 s (Hemochron; ITC, Edison, New 
Jersey, USA). A total of 30 mg kg- 1 of tranexamic acid was 
given before heparin and a second dose of 30 mg kg-1 was 
given after separation of CPB. 
Heparin neutralisation after CPB weaning was achieved 
with protamine chloride (MEDA Pharmaceuticals, Wan-
gen-Brüttisellen, Switzerland). The protamine dose was 
calculated as 80% of the total dose of heparin. 
Blood sampling 
Blood samples for anti-Xa act1v1ty measurement and 
ROTEM analysis were obtained through a central venous 
catheter and were collected in trisodium citrate antic-
oagulated 3 ml tubes (S-Monovette; Sarstedt, Nüm-
brecht, Germany). The first 10 ml of blood drawn were 
discarded to prevent preanalytical sources of error due to 
the dead volume of the central venous catheter. Blood 
samples were collected after sternotomy and before 
heparin administration (TO, baseline), 10 min after 
heparin administration before cannulation (Tl), at the 
end of CPB (T2) and 10 min after protamine adminis-
tration (T3). 
Anti-Xa activity measurement 
Serum heparin concentrations were determined by 
measuring anti-Xa activity using spectrophotometry (Sys-
max CA-7000; Siemens, Norderstedt, Germany). After 
centrifugation, a five-fold dilution using standard plasma 
Copyright© European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibite1 
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was necessary for the heparin concentration to drop 
within the Sysmax C-7000 detection limits. 
Rotational thromboelastometry analysis 
In ROTEM, the reagents used have the same names as 
their specific test. For the sake of clarity, we will use 
upper case letters to denominate tests and lower case 
italic to denominate reagents (e.g. EXTEM test and e:xtem 
reagent). 
All ROTEM analyses were performed by three regular 
staff members of the anaesthetic department who were 
trained and experienced in handling of the ROTEM 
analyser (FG, CMM, and MC). Test results were read 
and interpreted by GF and MC who were unblinded for 
test results at different time points. 
Three tests were performed using a ROTEJ\11 analyser 
dedicated to this study: 
(1) EXTEM: Initiation of coagulation through the 
extrinsic pathway. Twenty microlitre of extem reagent 
(rTF, phospholipids and heparin inhibitor in buffer) 
and 20 µ! of stmtem reagent (CaC12 0.2mol1- 1 in 
HEP ES buffer) are added to 300 µl of whole blood. 
(2) INTEM: Initiation of 'coagulation through the 
intrinsic pathway. Twenty microlitre of i11tem reagent 
(partial thromboplastin phospholipid and ellagic acid 
in buffer) and 20 µl of stmtem reagent are added to 
300 µl of whole blood. 
(3) HEPTEM: Twenty microlitre of i11tem reagent and 
20 µlof heptem reagent (heparinase in CaC12 solution) 
are added to 300 µl of whole blood 
Comparisons 
EXTEM 
EXTEM at TO was compared with Tl to detect the 
influence of heparin administration. EXTEM at Tl was 
compared with T2 to evaluate the changes in ROTEJ\11 
parameters due to CPB. EXTE.tvl at T2 was compared 
with T3 to evaluate whether heparin-induced changes, if 
present, were reversible with protamine. 
INTEM 
INTEM at TO was compared with HEPTElVl at TO to 
exclude any direct effect of the heptem reagent on the 
INTEM test. INTE.tvl at Tl and T2 could not be 
measured due to the strong effect of heparin on the test 
(fiat line INTEM tracing during CPB). INTEM at TO 
was, therefore, compared to HEPTE.tvl at Tl to detect 
any changes induced by the high heparin concentration. 
HEPTEM at Tl was compared to HEPTEM at T2 to 
evaluate the changes in ROTE:tv1 parameters due 
to CPB. Finally, HEPTEM at T2 was compared to 
INTE.tvl at T3. 
The following parameters were compared for all 
ROTEM tests: coagulation time expressed in seconds, 
angle (œ) expressed in degrees, amplitude at 10 min (AlO) 
and maximal clot firmness (MCF) bath expressed in 
millimetres and maximum lysis at 60 min expressed as 
a percentage. 
Reference ranges for EXTEivl in our institution are 
coagulation time 38 to 79s; angle 63 to 83°; AlO 43 to 
65 mm; MCF 50 to 72mm; and maximum lysis less than 
15%. Reference ranges for INTEM are coagulation time 
100 to 240 s; angle 70 to 83°; AlO 44 to 66 mm; MCF 50 to 
72 mm; and maximum lysis less than 15%. 
Statistical analysis 
Distribution analysis was performed with the Kolmo-
gorov-Smirnov test. To assess the mean differences 
between time points, a one-way analysis of variance 
(ANOV A) for repeated measurements was performed 
followed by post-hoc paired Student's t-test or Wilcoxon 
rank-sum test, when appropria te. P values were adjusted 
using the Bonferroni correction for multiple comparisons. 
P < 0.05 was considered statistically significant. Data 
were analysed using JMP 8.0 software (SAS Institute 
Inc., Cary, North Carolina, USA) and are presented as 
median (interquartile range, IQR) or mean (SD), unless 
otherwise specified. 
Sample size analysis 
The sample size needed for a paired Student's t-test with 
Bonferroni correction was calculated using the results of 
ROTEM measurements performed after protamine 
administration in historical patients in our institution. 
The eut-off values for treatment were defined in our 
local treatment algorithm (equal to the minimal normal 
values provided by the manufacturer). For the estimation 
of relevant differences between T2 and T3, we calcu-
lated the change in results in our historical patients that 
would have led to unwarranted therapeutic interventions 
according to our algorithm. Sample size analysis for a 
power of0.8 and œ of0.016 (0.05/3) yielded a sample size 
of 10 patients for coagulation time, 11 patients for AlO, 
five patients for JVlCF and 19 patients for alpha. 
Results 
A total of 22 patients were enrolled. The blood samples 
of the first two patients were used for calibration and 
validation of the dilution method for spectrophoto-
metric anti-Xa measurement. Complete data for 
EXTEM, INTEJVl and HEPTEM were obtained 111 
20 patients. Patient characteristics are summarised in 
Table 1. 
The results for activated partial thromboplastin time, 
ACT and anti-Xa activity are represented in Table 2. 
The mean (SD) total heparin dose used during CPB was 
576 (99)IUkg- 1• The mean ACT was 110 (ll)s at TO, 
552 (122)s at Tl, 495 (53)s at T2 and 118 (14) at T3. 
There were no significant differences for ACT between 
Tl and T2 (P= 0.06). Î\foan CPB duration was 
Eur J Anaesthesiol 2013; 30:1-8 
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Table 1 Patient's characteristics 
Patients (n) 
Age (yea_rs) 
Male sex 
i BSA (m2) 
ASÜ ··--
' A!>Jl ~-
Arterial hypertension 
'Diabetes 
· Peripheral artery dlsease 
Renal insufficiency 
History of myocardial infa.rction 
! History of angina 
History of cerebrovascular disease 
' Aspirin therapy 
Tobacco. use 
20 
69 (11) 
15 (75%) 
2.1 (0.4) 
2 (20%) 
18. (80%) 
f5 (76%) 
3 (14%) 
.... 4 (20%) 
3 (14%) 
5·(25%) 
5 (25%) 
. . .. 1 {5o/o) 
20 (1000/o) 
7 (33%) . 
ASA, American Society of Anesthesiologists; data are presented as number 
(proportion) or mean (SD). 
77 (22) min and duration of aortic cross-clamping was 
64 (22) min. The mean anti-Xa activity at Tl was 
7.77 (2.38) IU ml- 1 and remained stable throughout 
CPB [7.17 (2.84)IUml- 1 at T2, P=0.6]. The mean 
protamine dose administered for heparin reversai was 
393 011) ru kg- 1. 
The results for the EXTEM, INTEM and HEPTEM 
tests are presented in Tables 3 and 4, respectively. 
ROTEM parameter~s at TO for EXTEM and INTEivI 
were within normal ranges for ail patients. 
At TO, there was no difference between INTEM and 
HEPTE.tvI for any of the parameters. 
At Tl, after the addition of heparin, EXTEM signifi-
cantly differed from baseline for ail parameters except for 
MCF (Fig. 1). Coagulation time was prolonged by 26.7 s 
(95% confidence interval, CI 18.4 to 34.9, P < 0.0001). 
The œ angle was 3° lower (95% CI 1.0 to 5.4, P=0.006). 
AlO was reduced by 4.4 mm (95% CI 2.3 to 6.5, 
P=0.0004) and finally maximum lysis was 4% less 
(95% CI 2.1 to 6.0, P=0.0007) . 
Compared to the INTEM test at TO, HEPTEM at Tl 
showed markedly prolonged coagulation time by 47 s 
(95% CI 34.3 to 59.6, P > 0.0001), AlO was reduced by 
2.3mm (95% CI 0.5 to 4.0, P=0.01) and the œ angle was 
slightly but significantly reduced by 2° (95% CI 1.0 to 3.0, 
P = 0.0007). Maximum lysis increased by 4.5% (95% CI 
3.4 to 5.7, P<0.0001; Fig. 1) 
At T2, ail parameters related to fibrin-platelet interaction 
(ALPHA, AlO and MCF) deteriorated significantly com-
pared to the values before bypass at Tl in both EXTEM 
and HEPTEM tests. 
Finally, at T3 after heparin reversai, EXTEM and 
HEPTEM were comparable to EXTEM and HEPTEM 
at T2, except for AlO in the EXTEM test, which 
improved by 4.2 mm (95% CI 1.3 to 7.0, P = 0.0004 ). 
Table 2 Values for activated partial thromboplastin time, activated clotting time and anti·Xa activity at baseline (TO), after administration of 
heparin 300 IU kg-1 (T1), at unclamping of the aorta (T2) and after administration of protamine (T3) 
TO T1 T2 T3 
! aPTT ~s) 32.1 (3.7) >150 >150 41.8 (15) 
ACT (s) 110.2 (10.6) 552. 7 (122.2) 495.8 (53.7) 118.4 (14) 
Anti·Xa activity (U m1-:1~ 7.8 (2.4) 7.2 (2.8) 0.2 (0.1)' 
ACT, activated clotting time; aPTT, activated partial thromboplastin lime. Data are presented as mean (SD). 
Table 3 Rotational thromboelastometry values for EXTEM at baseline (TO), after administration of heparin 300 IU kg-1 (T1 ), at unclamping of 
the aorta (T2) and after administration of protamine (T3) 
EXTEM TO EXTEM T1 EXTEM T2 EXTEM T3 
i CT 50 (45 to 53] 72 [70 Io 81]* 66 [59 to 72]§ 62 (50 Io 69] 
a 75[73 to BO] 73 [68 to 77]* 66 [60 Io 70]§ if9 [64 Io 7()] 
A10 59 [56 to 63] 56 (49 té 60]* 48 [41 to 51]§ 52 (46 to 54]t 
MCF 66 [64 io 7o] 64 [61 Io 6B] 60 [57 to 63]§ 61 [55 Io 63] 
'ML 6 [4 to 9] 1 [O to 3]* 0 [O to1] 3 [2 to 4]t 
CT, coagulation lime; MCF, maximal clot firmness; ML, maximum lysis. * Different !rom EXTEM al baseline (TO). P< 0.05. § Different !rom EXTEM al T1. P< 0.05, 
tDifferent !rom EXTEM al T2. P<0.05. Data are presented as median [interquartile range, IOR], 
Table 4 Rotational thromboelastometry values for INTEM and HEPTEM at baseline (TO), after administration of heparin 300 IU kg-1 (T1 ), 
at unclamping of the aorta (T2) and after administration of protamine (T3) 
INTEM TO HEPTEMTÜ HEPTEM T1 HEPTEM T2 INTËMT3 
iCT 157 [137 Io 168] 156 [139 Io 164] 193 (183 to 214]* 183 [164 Io 201] 189 [164 to 200] 
a 78 [76 to 79] .. 78 [76 Io 80] .. 76 [74 Io 79]* 72 [67 to 74]* 74 [70 to 75] 
i A10 59 [55 Io 61] 58 [54 Io 61] 55 [53 Io 61]* 49 [41 to 51]* 51 [44 Io 54] 
MCF 64 [61 to 68] 62 [60 Io 68] 64 [61 io 6!3] 5!3 [54tà 61]*. 60 [53 to 63] 
; ML 6 [4 to8] 6 [4 Io 8] 1JO Io 2!* 1 [OtojI 3 [2 to 5]! 
Du ring cardiopulmonary bypass (CPB; T1 and T2,) INTEM yields no results. CT, coagulation time; MCF, maximal clot firmness; ML, maximum lysis. * Different !rom 1 NTEM 
al baseline (TO). P< 0.05. # Different !rom HEPTEM at T1. P< 0.05. t Different !rom HEPTEM at T2. P< 0.05. Data are presented as median [interquartile range, IOR]. 
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Fig. 1 
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seconds. (b) Angle (ALPHA) expressed in degrees. (c) Amplitude at 10 min (A 10) expressed in millimetres (mm). (d) Maximal clot firmness (MCF) 
expressed in millîmetres (mm). 
Discussion 
In this study, we validated the EXTEM and HEPTEIVI 
assays during CPB. The administration of heparin 
immediately induced significant changes in rTF and 
ellagic acid activated ROTEM parameters. Heparinase 
efficiently inactivated heparin in the HEPTE.rvl test 
during bypass. 
The cornparison of INTEM and HEPTEM at TO 
showed that the heptem reagent does not influence any 
of the parameters of the INTEl\!1 test. 
Comparison of the ROTEM parameters over time showed 
that the administration of heparin 300 UI kg-1 induced a 
significant change in all EXTfü\11 and HEPTEJVl 
parameters except for the MCF, that there is a progressive 
decline of the parameters during CPB, and finally, that all 
parameters remain stable after the administration 
of protamine. 
The changes we observed immediately following the 
administration of heparin (Fig. 2) are in contrast with 
the results reported by Gertler et a!. 12 who studied the 
influence on ROTEM of incremental doses of heparin 
added in vitro to whole blood. They found no difference 
between INTEM at baseline and HEPTEM at heparin 
concentrations up to 8 IU ml-1. 
Our finding can either be the consequence of a direct 
influence of heparin on the ROTEl\!1 test reagents (in 
which case, the tests would not be valid during CPB) or 
they may reflect real changes in haernostasis. On one 
hand, concerning a possible interaction with the 
ROTEM tests, the manufacturer guarantees stability 
of the extem reagent up to SUI ml- 1 of heparin, whereas 
we rneasured concentrations in excess of 7UI1111- 1. The 
extem reagent contains a non-specified heparin inhibitor, 
the concentration of which might not be sufficient to 
Eur J Anaesthesiol 2013; 30:1 -8 
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Fig. 2 
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(a) EXTEM traces at baseline (TO, outer trace) and after 300 IU kg-1 of heparin (T1, inner trace). (b) INTEM traces at baseline (TO, outer trace) and 
HEPTEM after 300 IU kg-1 of heparin (T1, inner trace). 
completely inhibit heparin at these concentrations. For 
the HEPTEM test, after the degradation of heparin by 
heparinase we expected the results to be identical to the 
INTEM before heparin administration. Comparing 
HEPTEM at Tl with baseline INTEM, however, we 
found most parameters to be altered significantly. This is 
in line with the findings of the study by Tuman et a/. 11 
conducted on TEG. One possible explanation could be 
Eur J Anaesthesiol 2013; 30:1 -8 
that the <limer and oligomers resulting from the cleavage 
of heparin may still have some min or anticoagulant effect. 
On the other hand, a part from the inhibition of factors Ila 
and Xa through enhancement of antithrombin, heparin 
has numerous endothelium-related effects on various 
elements of haemostasis. We believe that the changes 
measured at Tl are actual alterations in haemostasis 
Copyright© European Society of Anaesthesiology. Unauthorized reproduction of this article is prohibitE 
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rather than heparin-induced artefacts. First, in-vivo 
heparin rapidly displaces tissue factor pathway inhibitor 
(TFPI) from the endothelium. 13 The effect of heparin on 
TFPI is dose-dependent and peaks as soon as 3 to 10 min 
after intravenous heparin administration. 14 As its name 
suggests, TFPI inhibits the TF-VIIa complex, but it 
also inhibits factor Xa. Heparin increases the affinity of 
TFPI for Xa and accelerates the initial interaction 
between both molecules. 15 Second, intravenous heparin 
inhibits platelet rnacro-aggregation. 16 This effect is 
related to endothelial release of lipoprotein lipase. 17 
The resulting increase in plasmatic lipophospholipids 
and non-esterified fatty acids may inhibit synthesis of 
thromboxane A2, a patent platelet activator. 18 Due to 
the endothelial contribution to heparin's inhibitory 
effect on platelet aggregation, this phenomenon is 
not observed during in-vitro studies, and yet is always 
present after intravenous heparin administration. 19 
Heparinase neutralises heparin but has no influence 
on the anticoagulant proteins originating from the 
initial heparin-endothelial interaction. The absence of 
the endothelial effect of heparin in in-vitro study by 
Gertler et al. explains the difference in observations 
and illustrates the importance of in-vivo validation of 
tests on haemostasis. 
Comparison of the pararneters at T2 and T3 showed that 
there is no influence of heparin reversai. ROTEM 
parameters at the end of bypass (T2) were identical to 
the pararneters after protamine administration (T3). This 
confirms that the endothelial related rnechanisms, rather 
than a direct effect of heparin on the tests, were respon-
sible for the initial changes, as any direct effect on the test 
should dissipate after protamine administration. More-
over, the fact that heparin reversai shows no influence on 
ROTEM pararneters irnplies that ROTEJ\!1 rneasure-
rnents can reliably be performed by the end of bypass. 
The opportunity to evaluate the patient's haemostatic 
capacity before protamine administration can possibly 
eliminate any unnecessary delay before the initiation 
of procoagulant therapy. 
Although the differences we measured between tirne 
points were statistically significant, none of them were 
clinically relevant. With only a few exceptions, ail values, 
for ail participants, rernained within normal lirnits, 
demonstrating that ROTEM is a highly sensitive tool, 
detecting subclinical changes in haemostatic rnech-
anisrns. 
In this study, ail patients were given tranexamic acid 
before baseline measurements. The influence of heparin 
on the measurement of clot lysis is, therefore, biased. The 
administration of antifibrinolytic drugs in cardiac surgery, 
is a class I(A) recommendation,20 and part of routine 
patient management in our centre. Therefore, we 
decided not to omit this drug in our study . .r-.foreover, 
the omission would not reflect clinical reality and the 
results of this study would not have been applicable to 
our daily practice. 
In conclusion, we found that HEPTEM measurements 
are valid in the presence of very high heparin concen-
trations and that the extem reagent is stable in the pre-
sence of heparin concentrations exceeding 5UI1111- 1• 
Both HEPTEM and EXTEM can, therefore, be used 
to evaluate haernostasis during CPB. 
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